Sanofi Pasteur and MSD have announced the end of their European vaccines joint venture so that their own “distinct growth strategies” can be pursued instead. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sanofi,_msd_to_dismantle_vaccines_jv_1020306Astellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/astellas_bags_orphan_drug_status_for_aml_drug_1218291AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_buys_ionis_nash_candidate_1231077AstraZeneca has bumped up its stake in US biotech Moderna, which is pioneering the development of a new class of drugs made of messenger RNA, to nine percent. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_ups_stake_in_moderna_1095937Shire is reportedly making a move on Swiss biotech giant Actelion, according to UK newspaper The Sunday Times. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire_offers_12bn-plus_for_actelion_971484US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/bms_opdivo_cleared_for_monthly_use_1226100Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_gets_us_nod_for_shire_buy_1243748European regulators have accepted Sandoz’ marketing application for a biosimilar of Pfizer’s $9-billion-a-year anti-inflammatory Enbrel, the world’s fifth biggest selling drug. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sandoz_files_enbrel_biosimilar_in_the_eu_972256AstraZeneca is considering making a move on US group Medivation in a deal that could be worth around $7 billion, according to media reports. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/astrazeneca_eyeing_up_medivation_1020475Shire has now confirmed that it has thus far rejected three merger proposals from Takeda, the last one being valued at around $44 billion. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire_turns_down_takedas_advances_1232652
